Klaas H. Groenier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Klaas H. Groenier has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Geertruida Hendrika de Bock
University of Groningen, University Medical Center Groningen
13 shared publications - Gijs W. D. Landman
University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands
13 shared publications - Jing de Haan-Du
Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
13 shared publications - Nanne Kleefstra
University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands
12 shared publications - Brendy Wauben-Spaetgens
Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands
11 shared publications - Mathilde Jalving
University Medical Center Groningen, Groningen, The Netherlands
11 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Number of patients included in the analysis by each year
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Number of patients included in the analysis by each year
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Quality of glycemic control by cancer stage
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Quality of glycemic control by cancer stage
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on all-cause mortality in patients with T2DM only in Dutch primary care
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on all-cause mortality in patients with T2DM only in Dutch primary care
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Background:Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer.Methods:This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0–III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, accounting for individual expected survival relative to the general population and relevant disease (e.g., diabetes duration and medications) and individual (e.g., age and gender) characteristics.Results:Of the 71,648 linked cases, 620 had breast cancer, 774 had colorectal cancer, and 438 had prostate cancer, with follow-up data available for 6.4 (4.2–8.4), 5.6 (2.7–7.6), and 6.3 (4.5–8.2) years, respectively. Compared with patients with pre-diagnosis glycemic control at target, the HRs and 95% confidence intervals for mortality among those with pre-diagnosis glycemic control not at target were 1.40 (1.00–1.96) for breast cancer, 1.45 (1.12–1.88) for colorectal cancer, and 1.39 (0.98–1.98) for prostate cancer.Conclusions:Among patients with T2DM in Dutch primary care, poor glycemic control before diagnosis with breast and colorectal cancer can increase mortality compared with good control.Impact:Glycemic control prior to cancer diagnosis is of prognostic value.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Background:Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer.Methods:This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0–III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, accounting for individual expected survival relative to the general population and relevant disease (e.g., diabetes duration and medications) and individual (e.g., age and gender) characteristics.Results:Of the 71,648 linked cases, 620 had breast cancer, 774 had colorectal cancer, and 438 had prostate cancer, with follow-up data available for 6.4 (4.2–8.4), 5.6 (2.7–7.6), and 6.3 (4.5–8.2) years, respectively. Compared with patients with pre-diagnosis glycemic control at target, the HRs and 95% confidence intervals for mortality among those with pre-diagnosis glycemic control not at target were 1.40 (1.00–1.96) for breast cancer, 1.45 (1.12–1.88) for colorectal cancer, and 1.39 (0.98–1.98) for prostate cancer.Conclusions:Among patients with T2DM in Dutch primary care, poor glycemic control before diagnosis with breast and colorectal cancer can increase mortality compared with good control.Impact:Glycemic control prior to cancer diagnosis is of prognostic value.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Relative survival rates for cancer patients relative to the general Dutch population: stratified by HbA1c prior to cancer diagnosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Relative survival rates for cancer patients relative to the general Dutch population: stratified by HbA1c prior to cancer diagnosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Baseline characteristics of patients diagnosed with type 2 diabetes in Dutch primary care by cancer diagnosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Baseline characteristics of patients diagnosed with type 2 diabetes in Dutch primary care by cancer diagnosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on mortality among incident cancer patients with T2DM in multivariable analysis, relative to the general population
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on mortality among incident cancer patients with T2DM in multivariable analysis, relative to the general population
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1. from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Study flowchart for patients without cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1. from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Study flowchart for patients without cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on all-cause mortality in incident cancer patients with T2DM in Dutch primary care: Data since 2006
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
The role of glycemic control on all-cause mortality in incident cancer patients with T2DM in Dutch primary care: Data since 2006
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Cancer treatment by type of cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care
Cancer treatment by type of cancer